- Push-out Score determined
- After less than two years in the position
- Praise and thanks for Lawton
- Responsibilities redistributed
- Search for a successor
- Lawton said 114 words
(exechange) — Lexington, Massachusetts, June 16, 2020 — Alison Lawton, chief executive of Kaleido, leaves. As announced by Kaleido Biosciences Inc. in a news release and in a regulatory filing published on Tuesday, June 16, 2020, Alison Lawton leaves her post as chief executive officer at the clinical-stage healthcare company after less than two years in the role, effective immediately.
Kaleido will undertake a search for a successor.
Following Alison Lawton’s departure, the position of Chief Executive Officer will not be filled for the time being. Alison Lawton’s responsibilities are being redistributed.
“To return to the United Kingdom and attend to an unexpected family health matter”
Alison Lawton’s departure from the CEO post is explained as follows. Kaleido said: “Alison Lawton has chosen to step down from her position as President and Chief Executive Officer in order to return to the United Kingdom and attend to an unexpected family health matter. Ms. Lawton will continue to serve as a Director and special advisor to Kaleido and will support the company through this transition.”
Precise information regarding Alison Lawton’s future plans was not immediately available.
Kaleido said: “Alison Lawton has resigned as the Company’s President and Chief Executive Officer (“CEO”) effective June 16, 2020 to return to the United Kingdom and attend to an unexpected family health matter. Ms. Lawton informed the Board of Directors of her decision on June 14, 2020.”
Share price decline
The announcement follows a decline in Kaleido Biosciences Inc.’s share price of 55% since June 2019.
In the position of CEO since 2018
Alison Lawton became CEO of the Company in 2018.
Alison Lawton has served as the Company’s Chief Executive Officer and President and as a Director since August 2018.
Prior to becoming Chief Executive Officer, Lawton served as the Company’s President and Chief Operating Officer from December 2017 to August 2018.
Prior to joining the Company, Lawton was Chief Operating Officer at Aura Biosciences, Inc., an oncology therapeutics company, from January 2015 until December 2017, and, prior to joining Aura, served as a consultant to Aura from March 2014 to December 2014.
Before that, Lawton served as Chief Operating Officer at OvaScience Inc., a life sciences company, from January 2013 to January 2014.
In addition, from 2014 to 2017, Lawton served as a biotech consultant for various companies, including as Chief Operating Officer consultant at X4 Pharmaceuticals.
Prior to that, Lawton spent more than 20 years in various positions of increasing responsibility at Genzyme Corporation, a global biopharmaceutical company, and subsequently at Sanofi S.A., also a global biopharmaceutical company, following the acquisition of Genzyme by Sanofi in 2011.
Lawton currently serves as a member of the board of directors of ProQR Therapeutics N.V. and Verastem, Inc. and has served on those boards since September 2014 and November 2012, respectively.
Lawton previously served as a director at CoLucid Pharmaceuticals, Inc. from 2016 until its acquisition by Eli Lilly in 2017, as a director at Cubist Pharmaceuticals, Inc. from February 2012 to December 2014 until its acquisition by Merck, and as a director at Magenta Therapeutics, Inc. from May 2017 to March 2018.
She holds a B.Sc. in pharmacology from Kings College, University of London.
Push-out Score determined
The Push-out Score™ determined by exechange gauges the pressure surrounding the management change on a scale of 0 to 10.
exechange reached out to Kaleido and offered the company the opportunity to comment on the score.
Read the full story in the exechange report 25.2020 ($).